| Literature DB >> 35505177 |
Nima Najafi-Ghalehlou1, Alireza Feizkhah2, Mohammadreza Mobayen2, Zahra Pourmohammadi-Bejarpasi2, Shima Shekarchi3, Amaneh Mohammadi Roushandeh4, Mehryar Habibi Roudkenar5,6.
Abstract
Major breakthroughs and disruptive methods in disease treatment today owe their thanks to our inch by inch developing conception of the infinitive aspects of medicine since the very beginning, among which, the role of the regenerative medicine can on no account be denied, a branch of medicine dedicated to either repairing or replacing the injured or diseased cells, organs, and tissues. A novel means to accomplish such a quest is what is being called "medical biowaste", a large assortment of biological samples produced during a surgery session or as a result of physiological conditions and biological activities. The current paper accentuating several of a number of promising sources of biowaste together with their plausible applications in routine clinical practices and the confronting challenges aims at inspiring research on the existing gap between clinical and basic science to further extend our knowledge and understanding concerning the potential applications of medical biowaste.Entities:
Keywords: Benign tumours; Medical biowaste; Menstrual blood; Placenta; Regenerative medicine
Year: 2022 PMID: 35505177 PMCID: PMC9064122 DOI: 10.1007/s12015-022-10383-3
Source DB: PubMed Journal: Stem Cell Rev Rep ISSN: 2629-3277 Impact factor: 6.692
Fig. 1Shows the characterisation of USC. It has been demonstrated that AQP1 in proximal tubules forms a highly permeable water-specific channel. KRT18 is a critical element of epithelial intermediate filament. USCs lack tumorigenesis phenotype due to the lack of teratoma formation when injected into immunodeficient in vivo models. Type I USCs partially express AQP1, NPHS1, SLC12A1, UMOD, and KRT18 and few are positive for AQP2. Type II USCs barely express SLC12A1 and UMOD and are negative for the other renal markers. i expressed both in type I USCs and type II USCs, ii expressed partially in type I USCs, iii negative in type I USCs, iv expressed partially in type II USCs, v negative in type II USCs. AQP1; protein aquaporin-1, AQP2; protein aquaporin-2, KLF4; Krüppel-like factor 4, KRT18; keratin 18, MHC-I; major histocompatibility complex I, NG2; neural/glial antigen 2, NR3C2; nuclear receptor subfamily 3 group C member 2, Oct3/4; octamer-binding transcription factor 3/4, PDGF-rβ; platelet-derived growth factor receptor beta, SLC12A1; solute carrier family 12 member 1, SOX2; SRY-box transcription factor 2, SSEA-4; stage-specific embryonic antigen 4, UMOD; uromodulin, Vim; vimentin, vWF; von Willebrand factor, α-SMA;α-smooth muscle actin
Summary of the preclinical studies administering USCs
| Animal model | Animal groups | Conditions | Administration | Result | Reference | |
|---|---|---|---|---|---|---|
| 1 | Rat | cisplatin-induced AKI | -Improved histological damage -Improved renal function -Increased proliferation of renal tubular epithelial cells -decreased inflammatory and apoptosis markers | Su et al (S. B et al., 2019) | ||
| 2 | Rat | Ischemia reperfusion-induced AKI | -decreased serum creatinine and blood urea nitrogen at day 1 -decreased histological tubular injury score and apoptosis at days 7 and 14 | Tian et al (SF et al., 2017) | ||
| 3 | Rat | Ischemia reperfusion injury and gentamicin injection (dual-injury chronic kidney disease) | -Improved renal function -decreased degree of glomerular sclerosis and atrophic renal tubules -decreased fibrosis, and monocyte infiltration -elevated SOD-1 expression levels | Zhang et al (Z. C et al., 2020) [ | ||
| 4 | Mouse | Busulfan-induced NOA | USCs and exosomes injected and transplanted into the interstitial space in the testes | -Upregulation of Pou5f1, SYCP3, and Prm1 genes -promoted restoration of exogenous spermatogenesis in the testes | Deng et al (D. C et al., 2019) | |
| 5 | Mouse | -36 chronic liver injury -36 acute liver injury group | Carbon tetrachloride (CCl4)-induced acute/chronic liver injury intraperitoneally | - | -Improved hepatocyte degeneration and resolved liver fibrosis substantially in the hypoxia-pretreated USC-transplanted group -Improved abnormal liver function partially -Induced autophagy and promoted cell proliferation, migration, and colony formation followed by USC-elicited liver tissue recovery in hypoxia pretreatment -No significant difference in ALT and AST levels between the two groups | Hu et al (H. C et al., 2020) |
| 6 | Mouse | -6 female control -10 female PBS group -10 female USCsCon shRNA-Exos group -10 USCsshDMBT1 #1-Exos group | Streptozotocin-induced diabetes intraperitoneally | -citrate buffer -100 μL PBS injected subcutaneously at 4 injection site -200 μg USCsCon shRNA-Exos in 100 μL PBS injected subcutaneously at 4 injection site -200 μg USCsshDMBT1 #1-Exos in 100 μL PBS injected subcutaneously at 4 injection site | -enhanced proliferation and migration of wound healing-related cells including keratinocytes, fibroblasts, and vascular endothelial cells -angiogenic tube formation of endothelial cells | Chen et al (CY et al., 2018) |
| 7 | Rabbit | -10 experimental white rabbits -10 control white rabbits | cyclosporine A-induced immunosuppression at a dose of 5 mg/Kg per day | drain transferred between the two layers of the omentum of the rabbit through a ventral midline incision and fixed on the omentum by three interrupted 4/0 prolene sutures | -formed a tissue-engineered graft from multilayered urothelium -organised smooth muscle tissue after ureteral reconstruction | Zhao et al (Z et al., 2019) |
| 8 | Rat | -20 control SUI rats 20- experimental SUI rats | intravaginal balloon inflation-induced stress urinary incontinence (SUI) | -1 mL of 0.9% physiological saline injected locally in and around the pubococcygeus muscle - | -improve urodynamic parameters (MBV, ALPP) -promoted activation, proliferation, and differentiation of SCs -enhanced phosphorylation of extracellular-regulated protein kinases (ERK) -repaired the injured pubococcygeus muscle | Wu et al (W. R et al., 2019) |
| 9 | Rodent | -20 sham control female Sprague–Dawley (SD) rats -20 IC alone female Sprague–Dawley (SD) rats -20 IC + USCs female Sprague–Dawley (SD) rats | protamine/lipopolysaccharide (PS/LPS)-induced interstitial cystitis | -saline instillation - 10 mg/mL PS in the urinary bladder; 2 mg/mL LPS 30 min later, and the experimental conditions 45 min later - | -suppressed oxidative stress, inflammatory reaction, and apoptosis -ameliorated urinary bladder environmental condition | Li et al (L. J et al., 2017) |
| 10 | Rat | -24 normal control SD rats -24 T2D SD rats -24 T2D + USCs SD rats | streptozocin-induced type 2 diabetes | -standard diet - high-fat diet of 44.3 kJ/Kg calorific value consisted of 22% fat + 48% carbohydrate + 20% protein; 35 mg/Kg streptozotocin injected intraperitoneally twice to the T2D SD rats -high-fat diet of 44.3 kJ/Kg calorific value consisted of 22% fat + 48% carbohydrate + 20% protein; | -alleviated histological destruction and functional decline of pancreatic islet, left ventricle, glomerulus, and bladder micturition -inhibited fibrosis and apoptosis of myocardium, glomerulus, and detrusor -nsignificant decease of fasting blood glucose | Dong et al (D. X et al., 2016) |
Fig. 2Current standard six-part methodology conducted by stool banks. (A) Call for stool donors (B) Conduct an on-site screening and fill in an in-depth donor questionnaire (C) Manufacturing (D) random health status and vital signs checks (E) Fulfilment and (F) FMTmaterial quality and efficacy and patient safety
Fig. 3Shows the embryonic-derived biowaste, including placenta, amniotic membrane, and amniotic fluid
Fig. 4Illustrates the stem cells derived from the oral cavity
shows the surface markers of oral cavity stem cells
| Marker | DPSCs | SHED | PDLSCs | SCAP | DFPCs | GMSCs | DePDL |
|---|---|---|---|---|---|---|---|
| Embryonic Stem cell marker | |||||||
| Oct-4 | + | + | + | + | − | + | + |
| Nanog | + | + | − | − | − | + | NA |
| Mesenchymal markers | |||||||
| CD106 | − | − | − | + | − | + | NA |
| CD166 | + | + | + | + | + | − | + |
| Stem cell marker | |||||||
| SSEA-4 | + | + | − | + | + | + | NA |
| CD9 | + | − | + | + | + | + | NA |
| CD13 | + | − | + | + | + | + | NA |
| Nestin | + | + | + | + | + | − | NA |
| Notch-1 | + | − | − | − | + | + | NA |
| CD24 | − | − | − | + | + | + | NA |
| CD29 | + | − | + | + | + | + | NA |
| Haematopoietic marker | |||||||
| CD80 | − | − | − | + | − | − | NA |
| CD86 | − | − | − | + | − | − | NA |
| Multipotency | |||||||
| Chondro | + | + | + | − | + | + | NA |
| Myo | + | + | − | − | − | − | NA |
| Odonto | + | + | − | + | − | − | NA |
| Cardiomyo | + | − | − | − | − | − | NA |
| Hepatocyte-like cell | + | − | − | + | + | − | NA |
| Melanocyte | + | − | − | − | − | − | NA |
| Endothelial | − | + | − | − | − | − | NA |
| Cemento | − | − | + | − | + | − | NA |
| Endodermal | − | − | − | − | − | + | NA |
Summary of the registered clinical trials in www.ClinicalTrials.gov in regard with the administration of DMSCs
| Clinical trial identifier | The number of participants | Status | Study Title | Conditions | Interventions | Study Type | Phase | Study Design | Locations | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03386877 | First Posted: December 29, 2017 Actual Enrollment: 29 participants | Completed | Periodontal Regeneration Using Dental Pulp Stem Cells (DPSCs) | Periodontal Diseases | Procedure: periodontal regeneration | Interventional | Not Applicable | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment | CIR dental school Torino, Piedmont, Italy CIR Dental school Turin University Turin, Piedmont, Italy |
| 2 | NCT04641533 | First Posted: November 24, 2020 Actual Enrollment: 13 participants | Completed | Effect of Dental Pulp Stem Cells and L-PRF After Impacted Third Molar Extraction | Stem Cell Third Molar Periodontal Pocket | Procedure: L-PRF + DPSC Procedure: L-PRF | Interventional | Not Applicable | Allocation: Randomized Intervention Model: Crossover Assignment Intervention Model Description: Prospective within person randomised split-mouth study. Left and right surgical sites for each participant were randomized using an online generated list to determine test and positive control LM3. ( Masking: Double (Investigator, Outcomes Assessor) Masking Description: The random allocation list was generated by a periodontist (EEA), a clinical staff enrolled patients according to their reference date. The first allocation on the list was assigned to the right mandibular molar for each patient by the oral surgeon (SÇ) Primary Purpose: Prevention | Baskent University Ankara, Turkey |
| 3 | NCT02523651 | First Posted: August 14, 2015 Estimated Enrollment: 40 participants | Unknown | Periodontal Regeneration of Chronic Periodontal Disease Patients Receiving Stem Cells Injection Therapy | Periodontal Diseases | Genetic: DPSC injection Other: Placebo | Interventional | Phase 1 Phase 2 | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment | Capital Medical University School of Stomatology Beijing, Beijing, China |
| 4 | NCT03957655 | First Posted: May 21, 2019 Estimated Enrollment: 40 participants | Not yet recruiting | Safety and Efficacy of SHED for Decompensated Liver Cirrhosis | Liver Cirrhosis | Biological: SHED group | Interventional | Early Phase 1 | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Outcomes Assessor) Masking Description: Outcome assessors will be blind to the randomization results of the participants Primary Purpose: Treatment | Changhai Hospital Shanghai, Shanghai, China |
| 5 | NCT01814436 | First Posted: March 20, 2013 Estimated Enrollment: 80 participants | Unknown | Revitalisation of Immature Permanent Teeth With Necrotic Pulps Using SHED Cells | Dental Pulp Necrosis Permanent Incisor Avulsed by Trauma | Device: scaffold-free SHED-derived pellet | Interventional | Not Applicable | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | School of Stomatology, Fourth Military Medical University Xi'an, Shaanxi, China |
| 6 | NCT01357785 | First Posted: May 23, 2011 Estimated Enrollment: 35 participants | Unknown | Periodontal Tissue Regeneration Using Autologous Periodontal Ligament Stem Cells (PDLSC) | Periodontal Pocket | Procedure: Cell therapy | Interventional | Phase 1 | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | School of Stomatology, Fourth Military Medical University Xi'an, Shaanxi, China |
| 7 | NCT01082822 | First Posted: March 9, 2010 Estimated Enrollment: 35 participants | Unknown | Periodontal Ligament Stem Cell Implantation in the Treatment of Periodontitis | Chronic Periodontitis | Biological: cell sheet pellets and cell sheet fragment | Interventional | Phase 1 Phase 2 | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | Research and Develop Center for Tissue Engineering, Fourth Military Medical University Xi'an, Shaanxi, China |